MedTrace Logo

Clinical Trial to Evaluate the Efficacy and Safety of CKD-391

NCT02451098 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 385

Last updated 2016-01-28

No results posted yet for this study

Summary

A Multicenter, Randomized, Double-blind, Active-controlled, Parallel group, Factorial Design, Phase III Clinical Trial.

Conditions

Interventions

DRUG

Atorvastatin10mg, Ezetimibe10mg

Atorvastatin10mg, Ezetimibe 10mg (Duration: 8weeks)

DRUG

Atorvastatin10mg, Ezetimibe placebo

Atorvastatin10mg, Ezetimibe placebo(Duration: 8 weeks)

DRUG

Atorvastatin20mg, Ezetimibe10mg

Atorvastatin20mg, Ezetimibe 10mg (Duration: 8weeks)

DRUG

Atorvastatin20mg, Ezetimibe placebo

Atorvastatin20mg, Ezetimibe placebo(Duration: 8weeks)

DRUG

Atorvastatin40mg, Ezetimibe10mg

Atorvastatin40mg, Ezetimibe 10mg (Duration: 8weeks)

DRUG

Atorvastatin40mg, Ezetimibe placebo

Atorvastatin40mg, Ezetimibe placebo(Duration: 8weeks)

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • Ho-Jung Yoon, PhD · The Catholic University of Korea

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2015-10-31
Completion
2016-01-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02451098 on ClinicalTrials.gov